Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures.

"CONFLICTS OF INTEREST Guarantor of the article: Silvio Danese, MD. Specific author contributions: G.F. and S.D. initiated the study; D.G., S.R., F.F., and M.A. collected the data; D.G. and G.F. analyzed the data; D.G. and G.F. drafted the manuscript; S.D. critically revised the manuscript. Financial support: None to report. Potential competing interests: G.F. received consultancy fees from Ferring, MSD, AbbVie, Takeda, Janssen, Amgen, Sandoz, Samsung Bioepis, Celltrion; M.A. received consulting fees from Nikkiso Europe and lecture fees from Janssen, AbbVie and Pfizer; S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, Abbott (AbbVie) Laboratories, Merck and Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alfa Wasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor, and Johnson and Johnson; the remaining authors have no conflicts to disclose."

"Financial support: None to report."